ezetimibe has been researched along with Chronic Kidney Diseases in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.63) | 29.6817 |
| 2010's | 31 (81.58) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, S; Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Gao, Q; Kosiborod, M; Mues, KE; Rosenson, RS; Shaik, A | 1 |
| Cass, A; Gallagher, M; Hooi, L; Jardine, M; Jun, M; Rogers, K; Smyth, B; Sukkar, L; Talbot, B; Walker, R | 1 |
| Kaszyńska, M; Żebrowski, P | 1 |
| Chen, YM; Chiang, WC; Chou, YH; Chu, TS; Lai, TS; Lin, SL; Lin, YC; Tu, YK; Wu, HY | 1 |
| Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS | 1 |
| Goonasekera, MA; Haynes, RJ; Mafham, MM | 1 |
| Casula, M; Catapano, AL; Pirillo, A; Tokgözoğlu, L | 1 |
| Cannon, CP; Genest, J; Gupta, M; Mancini, GBJ; Raggi, P; Ray, KK; Santos, RD; Tsigoulis, M; Watts, GF | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamashita, T | 1 |
| Fukumoto, Y | 1 |
| Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E | 1 |
| Brownrigg, J; Catterick, D; Danese, MD; Gleeson, M; Khunti, K; Kondapally Seshasai, SR; Kutikova, L; Ray, KK; Sorio-Vilela, F | 1 |
| Baigent, C; Collins, R; Emberson, J; Gray, A; Haynes, R; Herrington, W; Kent, S; Landray, MJ; Mihaylova, B; Reith, C; Schlackow, I | 1 |
| Erickson, KF; Walther, CP | 1 |
| Banach, M; Katsiki, N; Mikhailidis, DP | 1 |
| Shoji, T | 1 |
| Krane, V; Schmidt, KR; Wanner, C | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y | 1 |
| Iwasaka, T; Jo, F; Kubo, R; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nakano, C; Okuno, Y; Seo, M; Shiojima, I; Someya, K; Takahashi, N; Toyoda, N; Ueda, H | 1 |
| Baigent, C; Blackwell, L; Emberson, J; Fellström, B; Haynes, R; Herrington, W; Hooi, LS; Landray, MJ; Levin, A; Massy, ZA; Reith, C; Staplin, N; Tesar, V; Walker, R | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Näsman, P | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Craig, JC; Palmer, SC; Strippoli, GF | 1 |
| Amadio, A; Harbin, M; Tejani, A | 1 |
| Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Baigent, C; Cass, A; Emberson, J; Gray, A; Haynes, R; Herrington, W; Landray, MJ; Mihaylova, B; Morton, RL; Schlackow, I; Staplin, N | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Wallén, H | 1 |
| Baigent, C; Cass, A; Collins, R; Craig, J; Emberson, J; Gray, A; Haynes, R; Herrington, W; Kent, S; Landray, MJ; Lozano-Kühne, J; Mihaylova, B; Reith, C; Schlackow, I | 1 |
| Cavanaugh, KL; Fagerlin, A; Wright Nunes, JA | 1 |
| Butler, CR; O'Hare, AM | 1 |
| Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Agodoa, L; Baigent, C; Emberson, J; Haynes, R; Herrington, W; Judge, PK; Landray, MJ; Lewington, S; Mafham, M; Reith, CA; Staplin, N; Tomson, C; Walker, R; Wheeler, DC; Wiecek, A | 1 |
| Pazianas, M | 1 |
| Jardine, AG; Stevens, KK | 1 |
| Agodoa, L; Armitage, J; Baigent, C; Baxter, A; Bray, C; Cass, A; Chen, Y; Chen, Z; Collins, R; Craig, J; Dasgupta, T; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Gaziano, M; Grimm, R; Grobbee, D; Grönhagen-Riska, C; Herrington, W; Hill, M; Holdaas, H; Hooi, LS; Jiang, L; Kasiske, B; Knott, C; Krairittichai, U; Krane, V; Landray, MJ; Levin, A; Lewis, D; Mafham, M; Majoni, W; Massy, ZA; Neal, B; Ophascharoensuk, V; Parish, S; Pedersen, T; Reith, C; Simpson, D; Sleight, P; Tesar, V; Tobert, J; Tomson, C; Walker, R; Wallendszus, K; Wanner, C; Wheeler, DC; Wiecek, A; Young, A | 1 |
| Green, D; McDonald, J; O'Riordan, E; Panayotova, R; Ritchie, JP | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP; Theocharidou, E | 1 |
9 review(s) available for ezetimibe and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Drug Combinations; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Patient Acuity; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors | 2021 |
LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
Topics: Antibodies, Monoclonal; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Renal Insufficiency, Chronic | 2020 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Renal Insufficiency, Chronic | 2019 |
Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Topics: Asian People; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Results of the 4D study: ten years of follow-up?
Topics: Adult; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Middle Aged; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin | 2012 |
Ezetimibe therapy for dyslipidemia: an update.
Topics: Animals; Anticholesteremic Agents; Azetidines; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic | 2013 |
15 trial(s) available for ezetimibe and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review.
Topics: Ezetimibe; Humans; Kidney; Kidney Transplantation; Renal Insufficiency, Chronic; Simvastatin | 2023 |
Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Prospective Studies; Renal Insufficiency, Chronic | 2018 |
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; United Kingdom; United States | 2019 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2013 |
Renal and vascular protective effects of ezetimibe in chronic kidney disease.
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors | 2014 |
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Topics: Aged; Anticholesteremic Agents; Azetidines; Catheterization; Cholesterol, LDL; Device Removal; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Reoperation; Simvastatin; Thrombosis; Vascular Access Devices; Vascular Patency | 2014 |
Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Chemokine CCL2; Cross-Over Studies; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Inflammation; Inflammation Mediators; Interferon-gamma; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2014 |
Critical appraisal of the SHARP trial: the results may be dull.
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic; United States | 2014 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Healthy Volunteers; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; NF-kappa B; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Taurine; Triglycerides; Tryptophan; Uric Acid | 2015 |
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Topics: Aged; Anticholesteremic Agents; Disease Progression; Educational Status; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Simvastatin; Vascular Diseases | 2016 |
Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin | 2016 |
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2017 |
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Topics: Adult; Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Simvastatin; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
14 other study(ies) available for ezetimibe and Chronic Kidney Diseases
| Article | Year |
|---|---|
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2022 |
[Ezetimibe as a treatment for dyslipidaemia in CKD].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2019 |
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Europe; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Renal Insufficiency, Chronic; United States | 2020 |
Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Topics: Aged; Angina, Unstable; Atherosclerosis; Cardiologists; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires | 2017 |
Impact of statin-ezetimibe combination in chronic kidney disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors | 2018 |
The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2019 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.
Topics: Adult; Anticholesteremic Agents; Child; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Nephrology; Practice Guidelines as Topic; Renal Insufficiency, Chronic | 2014 |
An Informed and Activated Patient: Addressing Barriers in the Pathway From Education to Outcomes.
Topics: Anticholesteremic Agents; Educational Status; Ezetimibe; Female; Humans; Male; Renal Insufficiency, Chronic; Simvastatin | 2016 |
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Clinical Decision-Making; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Health Services for the Aged; Humans; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Female; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Uric Acid | 2016 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
SHARP: a stab in the right direction in chronic kidney disease.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin; Treatment Outcome | 2011 |